Are your patients withholding the
impact OIC has on their lives?

A large, multinational survey across 5 European countries of patients
on strong opioids with OIC (N=2016) showed:1

More than


of patients expressed feelings of frustration and dependence caused by their OIC1

Another survey conducted in the United States, Canada, Germany, and the United
Kingdom in patients with OIC (N=489) revealed some possible reasons why
patients did not speak with their healthcare provider about their OIC:2
  • Concern about the need to reduce or change their pain medicine
  • Embarrassment
  • They ran out of time to discuss constipation

The dialogue about OIC starts with you

The more you see—and hear—what’s really happening, the better you’ll be
able to help your patients with OIC get the treatment they need.
of patients with OIC
can be identified by using a simple diagnostic
tool to ask about their constipation3
OIC, opioid-induced constipation.
Many patients with OIC taking opioids reduce their pain medication as a result of constipation.4
Find out why arrow icon
You can treat OIC without compromising pain control.5
Find out how arrow icon
References 1. Andresen V, Banjeri V, Hall G, Lass A, Emmanuel AV. The patient burden of opioid–induced constipation: new insights from a large, multinational survey in five European countries. United Eur Gastroenterol J. 2018;6(8):1254–1266. doi:10.1177/2050640618786145 2. LoCasale RJ, Datto C, Wilson H, Yeomans K, Coyne KS. The burden of opioid–induced constipation: discordance between patient and health care provider reports. J Manage Care Spec 𝘗𝘩𝘢𝘳𝘮. 2016;22(3):236–245. doi:10.18553/jmcp.2016.22.3.236 3. Davies A, Leach C, Butler C, et al. Opioid-induced constipation in patients with cancer: a “real-world,” multicentre, observational study of diagnostic criteria and clinical features. Pain. 2021;162(1):309-318. doi:10.1097/j.pain.0000000000002024 4. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35-42. doi:10.1111/j.1526-4637.2008.00495. 5. MOVENTIG Summary of Product Characteristics. Accessed May 2022. https://www.medicines.org.uk/emc/medicine/30483/smpc.

PRESCRIBING INFORMATION (prepared August 2021)

Moventig® (naloxegol oxalate) 12.5mg and 25mg film-coated tablets

Consult Summary of Product Characteristics (SmPC) before prescribing.
Indication: Opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s) (concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the previous 2 weeks).
Dosage and administration: Recommended 25 mg once daily. Take on empty stomach at least 30 minutes prior to first meal of day or 2 hours after first meal of day. Crushed tablets can be mixed with water (120ml) and drunk immediately or administered via a nasogastric tube (CH8 or greater). Renal impairment: Moderate or severe renal impairment starting dose 12.5mg. Discontinue if side effects impact tolerability. Increase to 25mg if well tolerated. Hepatic impairment: Use in severe hepatic impairment not recommended. Moderate CYP3A4 inhibitors: Starting dose 12.5mg, can be increased to 25mg if well tolerated. Paediatric population (<18 years): Safety and efficacy not yet established.
Adverse effects: Consult SmPC for full list of side effects. Very Common: Abdominal pain, diarrhoea. Common: Nasopharyngitis, headache, flatulence, nausea, vomiting, hyperhidrosis. Uncommon: Opioid withdrawal syndrome. Not known: Hypersensitivity, Gastrointestinalperforation.
Contraindications: Hypersensitivity to active substance or any of the excipients or any other opioid antagonist. Patients with known or suspected gastrointestinal (GI) obstruction or patients at increased risk of recurrent obstruction. Patients with underlying cancer who are at heightened risk of GI perforation, such as those with underlying malignancies of gastrointestinal tract or peritoneum, recurrent or advanced ovarian cancer or vascular endothelial growth factor (VEGF) inhibitor treatment. Concomitant use with strong CYP3A4 inhibitors.
Warnings and precautions: Cases of gastrointestinal perforation have been reported in the post-marketing setting, including fatal cases when naloxegol was used in patients who were at an increased risk of gastrointestinal (GI) perforation. Naloxegol must not be used in patients with known or suspected gastrointestinal obstruction or in patients at increased risk of recurrent obstruction. Use with caution in patients with any condition which might result in impaired integrity of the gastrointestinal tract wall. Advise patients to discontinue therapy and promptly report if unusually severe or persistent abdominal pain develops. Use with caution in patients with clinically important disruptions to the blood brain barrier and observe for potential CNS effects. Discontinue if interference with opioid-mediated analgesia or opioid withdrawal syndrome occurs. Use with caution in patients taking methadone. If opioid withdrawal syndrome is suspected the patient should discontinue Moventig and contact their physician. Use with caution in patients with a recent history of myocardial infarction, symptomatic congestive heart failure, overt cardiovascular (CV) disease or with a QT interval of ≥500msec. Use with caution in OIC patients with cancer-related pain. Use of naloxegol with another opioid antagonist (e.g. naltrexone, naloxone) should be avoided.
Use in pregnancy and lactation: Not recommended.
Legal category: POM.
Marketing Authorisation numbers: Moventig 12.5mg and 25mg tablets (ROI: EU/1/14/962/001-011),(GB: PL GB 50262/004&5)
Further information available on request from the Marketing Authorisation holder: Kyowa Kirin Holdings B.V., Bloemlaan 2, 2132NP Hoofddorp, The Netherlands.
For the United Kingdom:
NHS cost: Moventig 12.5mg, 30 tablets, £55.20; Moventig 25mg, 30 tablets, £55.20.
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com
For the Republic of Ireland:
Adverse Events should be reported. Information about adverse event reporting can be found at www.hpra.ie. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com
This program is best viewed on a device with a higher screen resolution. Some content may not be optimally presented.